Cargando…

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy

Detalles Bibliográficos
Autores principales:	Vojinovic, J, Basic, J, Susic, G, Jevtovic-Stoimenov, T, Damjanov, N, Pavlovic, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334097/ http://dx.doi.org/10.1186/1546-0096-6-S1-P38

Ejemplares similares

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

Influence of TNFα–308 and T676G TNF-RII polymorphism on response to etanercept and posibility to discontinue tretment
por: Vojinovic, J, et al.
Publicado: (2011)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
por: Vojinovic, J, et al.
Publicado: (2011)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
por: Susic, G, et al.
Publicado: (2013)

Understanding the biology and use of anti-TNF agents in JIA – interim results
por: Lovell, Daniel J, et al.
Publicado: (2012)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2225: Oxidative stress in children with episodic fever of unknown origin
por: Vojinovic, J, et al.
Publicado: (2013)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
por: Pontikaki, I, et al.
Publicado: (2008)

Use of anti-TNF Etanercept in paediatric patients with autoimmune disease and ocular involvement: the Parma experience
por: Rossi, M, et al.
Publicado: (2008)

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

A closer look into DNase I hypersensitivity
por: He, Housheng Hansen, et al.
Publicado: (2013)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011)

Influence of rhDNAse on the duration of mechanical ventilation in intensive care patients
por: Deschner, N, et al.
Publicado: (2008)

KIR-HLA class I combinations in JIA-associated uveitis
por: Parsa, Miriam, et al.
Publicado: (2012)

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
por: Salmaso, A, et al.
Publicado: (2008)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Does childhood health assessment questionnaire can predict outcome of patients with juvenile idiopathic arthritis?
por: Susic, G, et al.
Publicado: (2011)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

Does standard phisiotherapy influence the health-related quality of life of JIA patients?
por: Mendonça, TMS, et al.
Publicado: (2011)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Influence of rhDNAse on the duration of mechanical ventilation in intensive care patients: interim analysis of the LUFIT trial
por: Deschner, N, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_pabfvciafhmpadc5c40nldp0ij